The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) in coronavirus
disease 2019 (COVID-19) survivors who were diagnosed with acute pulmonary embolism …

Pulmonary hypertension (PH) is a progressive disease characterized by elevated artery
pressures and pulmonary vascular resistance. Underlying mechanisms comprise …

Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with
multiple myeloma and AL amyloidosis, while also indicated in Waldenström's …

Pulmonary arterial hypertension is a chronic, progressive disorder of the pulmonary
vasculature with associated pulmonary and cardiac remodeling. PAH was a uniformly fatal …

Background Among patients with heart failure with preserved ejection fraction (HFpEF), a
distinct hemodynamic phenotype has been recently described, ie, latent pulmonary vascular …

Background Pulmonary hypertension due to chronic obstructive pulmonary disease (COPD)
and interstitial lung disease (ILD) is classified as group 3 pulmonary hypertension. Inhaled …

Abstract Background The European Society of Cardiology (ESC) clinical practice guidelines
are essential tools for decision-making. Aim To analyze the level of evidence (LOE) and the …

Background Diagnostic rates and risk factors for the subsequent development of chronic
thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism (PE) are …

Pulmonary arterial hypertension (PAH) is a multifactorial disease associated with the
remodeling of pulmonary blood vessels. If left unaddressed, PAH can lead to right heart …

Pulmonary hypertension, frequently complicating the course of patients with fibrotic
interstitial lung disease, is associated with significantly increased morbidity and mortality …